Reuters logo
BRIEF-Veru Healthcare reports advancements in development of tamsulosin DRS for benign prostatic hyperplasia
July 20, 2017 / 1:07 PM / 2 months ago

BRIEF-Veru Healthcare reports advancements in development of tamsulosin DRS for benign prostatic hyperplasia

July 20 (Reuters) - Female Health Co:

* ‍Veru Healthcare-initiated subject screening process for stage 2 of bioequivalence study of tamsulosin drs for treatment of benign prostatic hyperplasia​

* ‍Veru Healthcare - initiated manufacturing of nda required registration batch through its contract manufacturer, which will be used for FDA submission​

* Veru Healthcare -manufacturing partner started production of commercial registration batch of tamsulosin drs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below